Journal of Immunology Research / 2022 / Article / Tab 3 / Research Article
High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration Table 3 Correlation between PDLIM2 protein expression and clinicopathological characteristics.
Variables PDL1M2 expression Total valueLow High Age (year) 0.006 0.939 ≤70 31 24 55 >70 44 35 79 Gleason score 7.047 0.029 6 21 7 28 7 18 24 42 >7 36 28 64 T stage 4.009 0.045 T1, T2, T3 31 18 49 T4 6 11 17 N stage 4.063 0.044 N0 67 46 113 N1 7 13 20 34β E12 1.011 0.315 Low 70 52 122 High 4 1 5 AR 2.106 0.147 Low 3 0 3 High 70 50 120 CK5/6 1.511 0.219 Low 64 49 113 High 2 0 2 Ki67 4.514 0.034 Low 49 25 74 High 23 26 49 P504s 1.653 0.199 Low 5 1 6 High 67 51 118 P53 0.033 0.855 Low 52 36 88 High 16 12 28 P63 0.096 0.757 Low 71 52 123 High 2 1 3 PSA 0.926 0.336 Low 13 6 19 High 60 46 106 PSAP 1.653 0.199 Low 5 1 6 High 67 51 118 SMA 2.981 0.084 Low 54 40 94 High 10 2 12 TOPO-II 0.324 0.569 Low 12 11 23 High 43 30 73 ERG 0.159 0.690 Low 46 38 84 High 11 11 22 P170 0.067 0.795 Low 52 38 90 High 5 3 8
Statistically significant (
). Abbreviations: AR: androgen receptor; PSA: prostate-specific antigen; PSAP: prostate-specific alkaline phosphatase; SMA: alpha-smooth muscle actin; TOPO-II: topoisomerase II; ERG: ETS-related gene.